Patent · US Active

Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

US10208307B2 · kind B2 · utility

11Cited by
11References
75Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 28, 2016
Grant dateFeb 19, 2019
Priority date
Expiry dateJul 28, 2036

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2320/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.